Vivos Therapeutics raises $4.6M via warrant exercise and issues new warrants for 3.96M shares

Vivos Therapeutics, Inc.

Gross proceeds of ~$4.6M from immediate cash exercise of existing warrants at reduced price of $2.34/share.
Issued Series A (5-yr) and Series B (24-mo) warrants to purchase up to 3,964,712 shares at $2.09/share.
Must file resale registration for new warrant shares by Feb 14, 2026; effective by Mar 16 or Apr 15 if SEC review.
Placement agent H.C. Wainwright paid 7% cash fee and received warrants for 138,765 shares at $2.925/share.
Until Feb 19, 2026, company restricted from issuing additional shares or filing registration statements.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Vivos Therapeutics, Inc. entered into Warrant Inducement Letter Agreement with an institutional investor valued at The Company agreed to issue warrants to purchase up to 3,964,712 shares of Common Stock at an exerci (effective 2026-01-15).

Action: entry
Agreement: equity purchase
Counterparty: an institutional investor
Value: The Company agreed to issue warrants to purchase up to 3,964,712 shares of Common Stock at an exerci
Effective: 2026-01-15

Exact text from the filing

On January 15, 2026, the Company entered into a warrant inducement letter agreement with the Holder (the “ Inducement Agreement ”) pursuant to which the Holder agreed to exercise for cash the entirety of the Warrants at a reduced exercise price of $2.34 per share (with such exercise price being established for purposes of compliance with the listing rules of the Nasdaq Stock Market), resulting in gross proceeds to the Company of approximately $4.6 million.

View on SEC.gov

304 material agreements filed in the last 30 days. Browse all material agreements →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-002844

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.